Explore groundbreaking studies, clinical trial updates, and emerging technologies shaping the future of cancer treatment.
Discover how targeting BTN2A1 with a unique activating monoclonal antibody enhances Vγ9Vδ2 T cell cytotoxicity against primary acute lymphoblastic leukemia blasts.